Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740985 | 0.87 | CA2 (0.49) | KDM4E | |
| SCHEMBL3740988 | 0.87 | CA2 (0.49) | KDM4E | |
| SCHEMBL13062319 | 0.85 | PTGS2 (0.39) | CYP3A4CSNK1D | |
| SCHEMBL13078268 | 0.85 | MAOB (0.40) | CYP3A4KCNH2SMN1; SMN2MAPT | |
| SCHEMBL13465337 | 0.79 | FOLH1 (0.40) | CYP3A4KCNH2PPARA | |
| SCHEMBL13464209 | 0.77 | ITGB3 (0.40) | CYP3A4KCNH2 | |
| SCHEMBL13062320 | 0.75 | CTSL (0.43) | — | |
| SCHEMBL13078235 | 0.75 | CTSL (0.43) | — | |
| SCHEMBL3738139 | 0.74 | CA2 (0.44) | KDM4E | |
| SCHEMBL3738134 | 0.74 | CA2 (0.44) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7829063-B2 | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317842-A1 | Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry | CA9, CA4, CA13 | CYP3A4 3277/4885KCNH2 2971/4885NPC1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.